ArticleInternational medical case reports journal2026
Reversal of Cerebral Glucose Hypometabolism in a Patient with COVID and Refractory B-Cell Lymphoma.
Article in International medical case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral glucose hypometabolism (CGHM) involves reduced brain glucose uptake on FDG-PET imaging and occurs in neurological and systemic diseases. Its reversibility remains uncertain. We describe a 40-year-old man with reversible global CGHM associated with cryptogenic organizing pneumonia (COP) and COVID-19. His neurocognitive symptoms improved rapidly following steroid-induced hyperglycemia, with FDG-PET demonstrating complete CGHM resolution after two months. His medical background included primary refractory transformed follicular lymphoma diagnosed 30 months earlier, managed with multiple treatment regimens including CAR-T therapy. After post-CAR-T relapse, combination therapy with polatuzumab vendotin, bendamustine, and obinutuzumab achieved complete remission, which was maintained when CGHM developed. This case establishes that CGHM can be temporary and reversible, highlighting a previously unrecognized pathway through which systemic illness may produce neurocognitive impairment. The rapid cognitive recovery coinciding with steroid-induced hyperglycemia and COP treatment is significant. Additional investigation is warranted to determine CGHM's significance in diverse pathological conditions and determine therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.